MDLA Enhances Market Leadership with New AAM–Merck Distribution Agreement

PT Medela Potentia Tbk (MDLA), through its subsidiary PT Anugrah Argon Medica (AAM), has officially been appointed as the distributor for PT Merck Tbk’s prescription pharmaceutical products in Indonesia.

The distribution agreement was formalized on 12 November 2025 at Titan Center, Bintaro, and signed by PT AAM President Director Ms. Juliwaty and Commercial Director Mr. Budi Lim, together with PT Merck Tbk President Director Ms. Evie Yulin and Finance Director Mr. Bambang Nurcahyo.

AAM President Director Ms. Juliwaty expressed appreciation for the trust extended by Merck in selecting AAM as its distribution partner.

“Today marks a significant milestone for AAM as we are officially entrusted to distribute Merck’s products starting 1 December 2025. The journey has not been easy, we underwent a rigorous and highly competitive selection process. We are grateful for the confidence Merck has placed in us,” she said.

Effective 1 December 2025, the partnership strengthens MDLA’s distribution portfolio across the pharmaceutical and medical device sectors. AAM and Merck will work together to enhance supply chain resilience, reinforce distribution data integrity, and expand market coverage for Merck’s healthcare products in Indonesia.

This agreement reinforces the confidence of global principals in AAM’s operational excellence, which consistently adheres to international standards.

PT Merck Tbk President Director Ms. Evie Yulin conveyed strong optimism for the renewed collaboration.

“PT Merck Tbk welcomes this opportunity to once again partner with AAM. Our expectations are high as external challenges continue to grow. We look forward to strong collaboration and full support from AAM in the field, guided by the spirit of As One for Patients, to ensure product availability for customers, especially patients,” she said.

PT Medela Potentia Tbk President Director Mr. Krestijanto Pandji stated that the partnership opens new revenue growth opportunities for MDLA’s distribution segment, supported by AAM’s extensive network and the strong market potential of Merck’s product portfolio.

He added that the agreement aligns with MDLA’s strategy to broaden its principal base and reinforce the Group’s position as a trusted distribution partner in Indonesia.

“The partnership between AAM and Merck not only enriches our distribution portfolio but also reflects the sustained confidence of global partners in our operational capabilities. MDLA remains committed to delivering long-term value for shareholders through strategic collaborations such as this,” Mr. Krestijanto said.

With continued trust from both national and multinational principals, AAM maintains strong and sustainable growth, underscoring the company’s operational strength and potential for further expansion in Indonesia’s rapidly growing healthcare sector.